DOSE DENSE ABVD (DD‐ABVD) AS FIRST LINE THERAPY IN EARLY‐STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.100_2630
Abstract: (HR (95% CI) = 0.600 (0.428-0.841)) . Multivariate Cox analysis with the interaction between treatment group and sCD30 level showed an increased risk of experiencing an mPFS event with ABVD and sCD30 >median (interaction p… read more here.
Keywords: dense abvd; abvd; dose dense; therapy ... See more keywords
Tumor progression and metastatic dissemination in ovarian cancer after dose‐dense or conventional paclitaxel and cisplatin plus bevacizumab
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Cancer"
DOI: 10.1002/ijc.31596
Abstract: The efficacy of therapeutic regimens incorporating weekly or every‐3‐weeks paclitaxel (PTX) for ovarian cancer is debated. We investigated the addition of bevacizumab in regimens of chemotherapy with different PTX doses and schedules in preclinical models.… read more here.
Keywords: tumor progression; ovarian cancer; dose dense; tumor ... See more keywords
Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-019-01567-y
Abstract: Background The purpose of this study was to determine the optimal regimen of neoadjuvant chemotherapy (NAC) for advanced epithelial ovarian, fallopian tube, and peritoneal cancers. Methods A clinical information survey involving 171 patients with advanced… read more here.
Keywords: paclitaxel carboplatin; epithelial ovarian; advanced epithelial; dose dense ... See more keywords
198P Complications associated with prolonged GCSF with dose-dense EC chemotherapy for early breast cancer patients
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Oncology"
DOI: 10.1016/j.annonc.2021.08.479
Abstract: Background: Primary granulocyte-colony stimulating factor (GSCF) prophylaxis with dose-dense chemotherapy for early stage breast cancer is routine practice to prevent febrile neutropenia (FN). Our current practice administers 7 days of GCSF, which reduces the FN… read more here.
Keywords: gcsf; dense; breast cancer; toxicity ... See more keywords
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01256-8
Abstract: The most common chemotherapy backbone for children with mature B-non Hodgkin lymphoma (B-NHL), Burkitt’s lymphoma (BL), and diffuse large B-cell lymphoma includes short intensive therapy including steroids, high dose methotrexate, fractionated cyclophosphamide, anthracycline, and intrathecal… read more here.
Keywords: lymphoma; risk; dense rituximab; dose dense ... See more keywords
O1-10-1Feasibility study of Dose-dense AC or EC followed by PTX for Japanese breast cancer patients
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx697.023
Abstract: Background: Dose-dense(D-D) chemotherapy for operable breast cancer revealed significant survival benefit compared to the standard chemotherapy. In western countries, it has become a standard of care. Whereas in Japan, owing to the unapproval of G-CSF… read more here.
Keywords: chemotherapy; study; breast cancer; dose dense ... See more keywords
Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumour infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz241.008
Abstract: Abstract Background Inflammatory breast cancers (IBC) particularly triple negative (TN) subtype have poor prognosis. Methods Between January 2010 and December 2016, all patients with TNIBC seen at breast cancer disease center, St Louis hospital, Paris,… read more here.
Keywords: chemotherapy; breast; breast cancers; inflammatory breast ... See more keywords
Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel–carboplatin combination therapy in patients with epithelial ovarian cancer?
Sign Up to like & getrecommendations! Published in 2017 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000538
Abstract: The aims of this study were to investigate a clinical observation that patients with epithelial ovarian cancer treated with first-line platinum–paclitaxel chemotherapy combination (TP) develop macrocytosis and to explore the possible predictive role of macrocytosis… read more here.
Keywords: macrocytosis; patients treated; schedule; dose dense ... See more keywords
Rituximab, interferon‐alfa‐2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH‐PRO‐05 study
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.15760
Abstract: Sarah Davis Steve Goodacre Abdullah Pandor Daniel Horner John W. Stevens Kerstin de Wit Beverley J. Hunt ScHARR, University of Sheffield, Sheffield, UK, Emergency Department, Salford Royal NHS Foundation Trust, Salford, UK, Department of Medicine,… read more here.
Keywords: interferon alfa; alfa dose; dense cvp; rituximab interferon ... See more keywords
Abstract GS4-03: Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: Results from the neoadjuvant part of ADAPT HR+/HER2- trial
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-gs4-03
Abstract: Background: Pathological complete response (pCR) is associated with improved outcome in patients with high-risk HR+/HER2- breast cancer (BC) but the use of (neo)adjuvant chemotherapy in early HR+/HER2- BC remains controversial. Oncotype DX / Recurrence Score… read more here.
Keywords: dose dense; high risk; risk her2; risk ... See more keywords
Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates
Sign Up to like & getrecommendations! Published in 2018 at "Breast Care"
DOI: 10.1159/000488026
Abstract: Adjuvant chemotherapy has greatly improved the prognosis of early breast cancer. Dose-dense chemotherapy seeks to increase efficacy by changing the interval between cycles of treatment without the need of increasing doses and toxicity. According to… read more here.
Keywords: chemotherapy; dose dense; dense chemotherapy; breast cancer ... See more keywords